Restless Legs SyndromeNCT00051961
Effect of Ropinirole on Spinal Cord Reflexes and Restless Legs Syndrome
An observational study of Restless Legs Syndrome, run by National Institute of Neurological Disorders and Stroke (NINDS) at 1 site in United States.
Trial summary
This study will examine the effects of the drug Ropinirole on spinal cord reflexes and on symptoms of restless legs syndrome (RLS). Patients with RLS have uncomfortable sensations in the legs, usually in the evening or early part of the night. Most patients also have periodic involuntary leg movements. Read more about this study
- Who is it for?
- Ages 18 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Restless Legs Syndrome
- How many people
- 90 participants
- Where
- 1 siteUnited States
- Study dates
- 14 Jan 2003to 18 Oct 2007
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Subjects who meet all of the following inclusion criteria at screening or Day 0 will be eligible to participate in the study:
- Male or female subjects aged 18 to 80.
- Body Mass Index within the range 19-34 kg/m(2) inclusive.
- For patients only, diagnosed with mild to moderate RLS based on the presence of a characteristic clinical history and the IRLSSG diagnostic criteria.
- Normal physical and neurological examination.
- Subject is willing to adhere to protocol requirements as evidenced by written, informed consent.
Show all 12Show fewer
- No clinical significant abnormalities on clinical chemistry or haematology examination at the pre-study medical evaluation.
- A normal 12 lead ECG at the pre-study medical.
- A negative pre-study Hepatitis B surface antigen and Hepatitis C antibody result within 3 months of the start of the study.
- Negative pre-study urine drug screen.
- RLS Rating Scale score of greater than or equal to 15 at the time of baseline evaluation, after medication wash out.
- Presence of PLMs by convincing history, or document by SIT or polysomnography tests at the time of baseline evaluation.
Who cannot join
- Subjects meeting any of the following exclusion criteria either at Day 0 or during the study will not be enrolled or will be immediately excluded from the study, as appropriate:
- History of any medical condition that can reasonably be expected to subject the individual to unwarranted risk or compromise scientific integrity of the study;
- History or presence of gastro-intestinal, hepatic or renal disease or other condition known to interfere with the absorption, distribution, metabolism or excretion drugs
- Clinically significant laboratory abnormalities including liver enzyme elevation greater than twice the upper limit of normal;
- Patient unwilling or unable to stop their usual medications for RLS;
- Subjects unable or unwilling to discontinue a prohibited concomitant medication;
Show all 21Show fewer
- Subjects who have received prescribed medication within 7 days prior to the first dosing day (defined as Day 1), which in the opinion of the Principal Investigator will interfere with the study procedures or compromise safety.
- Withdrawal, introduction, or change in dose of hormone replacement therapy (HRT) and/or any drug known to substantially inhibit or induce CYP1A2 within 2 weeks prior to first dose (Day 1).
- Patients suffering from RLS symptoms during the daytime (daytime defined as 10.00 until 16.00 hours).
- Subjects who have not been using a clinically accepted contraceptive method (such as oral contraception, surgical sterilization, IUD, diaphragm in conjunction with spermicidal foam and condom on the male partner, or systemic contraception) for the last 30 days, or is not at least one year post-menopausal (if female);
- Subjects who are pregnant or breastfeeding;
- Subjects with cognitive impairment (MMSE less than 25);
- Subjects who have participated in a clinical study with an investigational drug within the last 3 months;
- Subjects with history or presence of active drug or alcohol abuse that, in the opinion of the investigators, would interfere with compliance or safety or scientific integrity of study;
- Subjects unwilling to sign an informed consent or to comply with protocol requirements.
- A dissomnia or parasomnia other than, in patients, primary RLS (e.g. narcolepsy, sleep tenor disorder, sleepwalking disorder, and breathing-related sleep disorder), either from clinical review or from polysomnography (including subjects with apnea hypopnea index greather than 5/h).
- Signs of secondary RLS (e.g. renal failure (end-stage renal disease), iron deficient anemia or pregnancy at baseline).
- Subjects with clinical and/or biochemical evidence of iron deficiency.
- Subjects with a diastolic blood pressure greater than or equal to 110mmHg or less than or equal to 50mmHg OR systolic blood pressure greater than or equal 180mmHg or less than or equal 90mmHg at baseline.
- Subjects with known intolerance to ropinirole or other dopaminergic agonist.
- Patients with symptomatic orthostatic hypotension.
Trial locations and contacts
1 site in 1 country.
United States1 site
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, 20892
About this study
Official title: Effects of Dopaminergic Agonist Treatment on Spinal Cord Excitability in Restless Legs Syndrome
This study will examine the effects of the drug Ropinirole on spinal cord reflexes and on symptoms of restless legs syndrome (RLS). Patients with RLS have uncomfortable sensations in the legs, usually in the evening or early part of the night. Most patients also have periodic involuntary leg movements. The condition tends to worsen over time, resulting in severe discomfort and sleep disturbances. Ropinirole affects chemical messengers thought to be involved in spinal cord function and in modulating RLS symptoms.
Healthy normal volunteers and patients with RLS between 18 and 80 years of age may be eligible for this study. Patients must have mild to moderate RLS and periodic limb movements. All candidates will be screened with a medical history, physical and neurological evaluations, electromyogram (see below), polysomnogram (see below), electrocardiogram (ECG), and blood and urine tests. They may also have magnetic resonance imaging (MRI) or computerized tomography (CT) scans and a chest x-ray. Participants must stop taking all medications prohibited by the study for at least 1 week before the study starts and throughout its duration.
Read more
The study will last approximately 2 to 3 weeks for healthy volunteers and 7 to 8 weeks for patients. Participants will undergo the following baseline evaluations: electroencephalography (EEG), a measure of brain wave activity; polysomnography (PSG), an overnight sleep study; electromyography (EMG), a measure of muscle activity; and spinal flexor reflex studies (spinal cord responses to electrical stimulation). For these studies, several electrodes are attached to the scalp or to the legs and arms using a cream that helps conduct brain signals through the cables to be recorded. The nervous system activity can be assessed at rest or after stimulation with an electric current. For EMG, a small needle is inserted into a few muscles and the subject is asked to relax or to contract the muscles. The electrical activity of the muscle cells is recorded and analyzed by a computer. Spinal flexor reflex studies usually involve stimulating the nerves in the legs with very brief electric currents of mild to moderate intensity. Flexor reflex studies will be done early in the night while the subject is awake and also during sleep. Brain, muscle and breathing activities will be monitored continuously during sleep.
A suggested immobilization test (SIT) will be done around 10 p.m. During the test, the subject sits still for about 1 hour, while the leg muscle activity is recorded using special electronic devices attached to the skin. At the end of the test, volunteers will be asked questions about symptoms they may have experienced during the test, and patients will be asked questions about their RLS symptoms during the test.
After the baseline tests, participants will be randomly assigned to take either Ropinirole tablets or a placebo (a look-alike inactive substance) daily for 5 weeks. They will be admitted to the NIH Clinical Center for 3 to 4 nights at the end of the second week and for 2 nights at the end of the study to repeat the baseline tests described above. Volunteers will take Ropinirole or placebo daily for 1 week. They will be admitted to the Clinical Center for 3 to 4 days at the beginning and then at the end of the study for repeat testing.
Medical examinations, ECGs and blood tests will be done at various times during the study for safety monitoring. Patients' blood pressure will be monitored weekly. Small amounts of blood will be drawn up to three times each day for routine studies, research and drug levels. Throughout the study volunteers will complete questionnaires for evaluation of possible RLS symptoms, and patients will have their symptoms assessed using a RLS Severity Rating Scale. Two weeks after the study ends, participants will be interviewed by telephone about any adverse experiences.
Read the detailed description
The objective of this study is to evaluate the effects of stimulation of dopaminergic D2, D3 receptors on spinal cord excitability and on the severity of symptoms in patients with mild to moderately advanced restless legs syndrome. In a controlled proof-of-principle clinical study, the acute efficacy of ropinirole will be assessed through the use of validated electrophysiological tests and severity scales. Safety will be monitored by means of frequent clinical evaluations and laboratory tests.
- Conditions
- Restless Legs Syndrome
- Keywords
- Dopamine, Spinal Physiology, Flexor Reflex, Ropinirole, Motor Control, Dopaminergic, Restless Legs
- Medical subject headings
- Restless Legs Syndrome
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Jan 2003 (estimated)
- Study start14 Jan 2003
- Study completion18 Oct 2007
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Restless Legs SyndromeStudies of the same condition, open and under way.
- More trials run by National Institute of Neurological Disorders and Stroke (NINDS)The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Enrolment
- 90 participants
Sponsor and investigators
- Sponsor type
- US National Institutes of Health
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00051961
- Sponsor's protocol ID
- 030075
- Other IDs
- 03-N-0075
- Status last verified
- 18 Oct 2007
- First submitted
- 17 Jan 2003
- Last updated
- 2 Jul 2017
- Results posted
- No
Publications
Trenkwalder C, Hening WA, Walters AS, Campbell SS, Rahman K, Chokroverty S. Circadian rhythm of periodic limb movements and sensory symptoms of restless legs syndrome. Mov Disord. 1999 Jan;14(1):102-10. doi: 10.1002/1531-8257(199901)14:13.0.co;2-e.
PubMed 9918351
Study at a glance
From the registry record, last updated by the sponsor on 2 Jul 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Dopaminergic Agonist Treatment on Spinal Cord Excitability in Restless Legs Syndrome
- ClinicalTrials.gov ID
- NCT00051961
- Acronym / sponsor ID
- 030075
- Conditions
- Restless Legs Syndrome
- Keywords
- Dopamine, Spinal Physiology, Flexor Reflex, Ropinirole, Motor Control, Dopaminergic, Restless Legs
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 90 participants
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)US National Institutes of Health
- Study start
- 14 Jan 2003
- Study completion
- 18 Oct 2007
- First posted
- 20 Jan 2003 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will examine the effects of the drug Ropinirole on spinal cord reflexes and on symptoms of restless legs syndrome (RLS). Patients with RLS have uncomfortable sensations in the legs, usually in the evening or early part of the night. Most patients also have periodic involuntary leg movements. The condition tends to worsen over time, resulting in severe discomfort and sleep disturbances. Ropinirole affects chemical messengers thought to be involved in spinal cord function and in modulating RLS symptoms.
Healthy normal volunteers and patients with RLS between 18 and 80 years of age may be eligible for this study. Patients must have mild to moderate RLS and periodic limb movements. All candidates will be screened with a medical history, physical and neurological evaluations, electromyogram (see below), polysomnogram (see below), electrocardiogram (ECG), and blood and urine tests. They may also have magnetic resonance imaging (MRI) or computerized tomography (CT) scans and a chest x-ray. Participants must stop taking all medications prohibited by the study for at least 1 week before the study starts and throughout its duration.
The study will last approximately 2 to 3 weeks for healthy volunteers and 7 to 8 weeks for patients. Participants will undergo the following baseline evaluations: electroencephalography (EEG), a measure of brain wave activity; polysomnography (PSG), an overnight sleep study; electromyography (EMG), a measure of muscle activity; and spinal flexor reflex studies (spinal cord responses to electrical stimulation). For these studies, several electrodes are attached to the scalp or to the legs and arms using a cream that helps conduct brain signals through the cables to be recorded. The nervous system activity can be assessed at rest or after stimulation with an electric current. For EMG, a small needle is inserted into a few muscles and the subject is asked to relax or to contract the muscles. The electrical activity of the muscle cells is recorded and analyzed by a computer. Spinal flexor reflex studies usually involve stimulating the nerves in the legs with very brief electric currents of mild to moderate intensity. Flexor reflex studies will be done early in the night while the subject is awake and also during sleep. Brain, muscle and breathing activities will be monitored continuously during sleep.
A suggested immobilization test (SIT) will be done around 10 p.m. During the test, the subject sits still for about 1 hour, while the leg muscle activity is recorded using special electronic devices attached to the skin. At the end of the test, volunteers will be asked questions about symptoms they may have experienced during the test, and patients will be asked questions about their RLS symptoms during the test.
After the baseline tests, participants will be randomly assigned to take either Ropinirole tablets or a placebo (a look-alike inactive substance) daily for 5 weeks. They will be admitted to the NIH Clinical Center for 3 to 4 nights at the end of the second week and for 2 nights at the end of the study to repeat the baseline tests described above. Volunteers will take Ropinirole or placebo daily for 1 week. They will be admitted to the Clinical Center for 3 to 4 days at the beginning and then at the end of the study for repeat testing.
Medical examinations, ECGs and blood tests will be done at various times during the study for safety monitoring. Patients' blood pressure will be monitored weekly. Small amounts of blood will be drawn up to three times each day for routine studies, research and drug levels. Throughout the study volunteers will complete questionnaires for evaluation of possible RLS symptoms, and patients will have their symptoms assessed using a RLS Severity Rating Scale. Two weeks after the study ends, participants will be interviewed by telephone about any adverse experiences.
Detailed description
The objective of this study is to evaluate the effects of stimulation of dopaminergic D2, D3 receptors on spinal cord excitability and on the severity of symptoms in patients with mild to moderately advanced restless legs syndrome. In a controlled proof-of-principle clinical study, the acute efficacy of ropinirole will be assessed through the use of validated electrophysiological tests and severity scales. Safety will be monitored by means of frequent clinical evaluations and laboratory tests.
Study design
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (12 listed)
- Subjects who meet all of the following inclusion criteria at screening or Day 0 will be eligible to participate in the study:
- Male or female subjects aged 18 to 80.
- Body Mass Index within the range 19-34 kg/m(2) inclusive.
- For patients only, diagnosed with mild to moderate RLS based on the presence of a characteristic clinical history and the IRLSSG diagnostic criteria.
- Normal physical and neurological examination.
Key exclusion criteria (21 listed)
- Subjects meeting any of the following exclusion criteria either at Day 0 or during the study will not be enrolled or will be immediately excluded from the study, as appropriate:
- History of any medical condition that can reasonably be expected to subject the individual to unwarranted risk or compromise scientific integrity of the study;
- History or presence of gastro-intestinal, hepatic or renal disease or other condition known to interfere with the absorption, distribution, metabolism or excretion drugs
- Clinically significant laboratory abnormalities including liver enzyme elevation greater than twice the upper limit of normal;
- Patient unwilling or unable to stop their usual medications for RLS;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jul 2017.
- Background: PubMed 9918351Trenkwalder C, Hening WA, Walters AS, Campbell SS, Rahman K, Chokroverty S. Circadian rhythm of periodic limb movements and sensory symptoms of restless legs syndrome. Mov Disord. 1999 Jan;14(1):102-10. doi: 10.1002/1531-8257(199901)14:13.0.co;2-e.
Related trials for Restless Legs Syndrome
RecruitingObservational study
Lemborexant vs Clonidine vs Sedatives to Treat Insomnia in Chronic Pain Patients
Chronic Insomnia, Chronic Pain
Not yet recruiting
Neuromodulation to Overcome Severe Restless Legs Syndrome
Restless Leg Syndrome (RLS), Spinal Cord Stimulation (SCS)
Not yet recruitingPhase 2
Tolerability and Efficacy of CBD Extract for RLS Treatment
Restless Leg Syndrome
Recruiting
Functional Connectivity of the Interoceptive Network in RLS
Restless Legs Syndrome
Not yet recruitingPhase 2
Intravenous Iron in the Management of Drug-resistant Restless Legs syndromeI
Restless Legs Syndrome (RLS)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Restless Legs Syndrome, run by National Institute of Neurological Disorders and Stroke (NINDS) at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 21 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Jul 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00051961, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jul 2017.